Related Experiment Video
Updated: Jun 13, 2025

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Individualized tacrolimus therapy: Insights from CYP3A5 polymorphisms and intestinal metabolism
Mizuki Mishima1, Tomohisa Yabe1, Takaya Kondo1
1Department of Nephrology Kanazawa Medical University Kahoku Japan.
Abstract:
CYP3A4 and CYP3A5 are the most abundant and important enzymes of the CYP3A subfamily, distributed in the liver, intestinal mucosa and kidney, and involved in tacrolimus metabolism. Here, we report a case of tacrolimus dosage refractoriness due to a genetic polymorphism of CYP3A5.
More Related Videos
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Hepatic Drug Clearance: Role of Transporters
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
Nonlinear Pharmacokinetics: Role of Transporters
Polymorphisms occurring in drug transporters can alter...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...

